Grundlagen und Klinik der Knochenmetastasen

  • R. Ebert
  • F. Jakob
Part of the Fortbildung Osteologie book series (FORTOSTEO, volume 1)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adiga GU, Dutcher JP, Larkin M, Garl S, Koo J (2004) Characterization of bone metastases in patients with renal cell cancer. BJU Int 93(9):1237–1240CrossRefPubMedGoogle Scholar
  2. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing sceletal events in patients with advanced multiple myeloma. N Engl J Med 334:488–493CrossRefPubMedGoogle Scholar
  3. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS (2002) American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20(17):3719–3736CrossRefPubMedGoogle Scholar
  4. Berenson JR (2002) Treatment of Hypercalcemia of Malignancy With Bisphosphonates. Sem Oncol 29(6) Suppl 21:12–18Google Scholar
  5. Berenson J, Hirschberg R (2004) Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist 9(3):319–329CrossRefPubMedGoogle Scholar
  6. Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C (2003) Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 278(44):43603–43614. Epub 2003 Aug 20CrossRefPubMedGoogle Scholar
  7. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS (2004) The Wnt Antagonist Secreted Frizzled-Related Protein-1 is a Negative Regulator of Trabecular Bone Formation in Adult Mice. Mol Endocrinol 18(5):1222–1237CrossRefPubMedGoogle Scholar
  8. Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergstrom B (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111(3):306–312CrossRefPubMedGoogle Scholar
  9. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2003) MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14(9):1399–1405CrossRefPubMedGoogle Scholar
  10. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133–1137CrossRefPubMedGoogle Scholar
  11. Body JJ, Mancini I (2003) Treatment of tumor-induced hypercalcemia: a solved problem? Expert Rev Anticancer Ther 3(2):241–246CrossRefPubMedGoogle Scholar
  12. Body JJ (2003) Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast 12(Suppl 2):S37–44PubMedGoogle Scholar
  13. Brown JE, Neville-Webbe H, Coleman RE (2004) The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 11(2):207–224CrossRefPubMedGoogle Scholar
  14. Campbell PG, Andress DL (1997) Insulin-like growth factor (IGF)-binding protein-5-(201–218) region regulates hydroxyapatite and IGF-I binding. Am J Physiol 273(5 Pt 1):E1005–1013PubMedGoogle Scholar
  15. Carr DB, Goudas LC, Balk EM, Bloch R, Ioannidis JP, Lau J (2004) Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr. (32):23–31PubMedGoogle Scholar
  16. Chang CH, Tsai CS, Jim YF, Wu HC, Lin CC, Kao A (2003) Lumbar bone mineral density in prostate cancer patients with bone metastases. Endocr Res 29(2):177–182PubMedGoogle Scholar
  17. Cheng YY, Huang L, Lee KM, Li K, Kumta SM (2004) Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 42(5):410–415CrossRefPubMedGoogle Scholar
  18. Clamp A, Danson S, Nguyen H, Cole D, Clemons M (2004) Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 5(10):607–616CrossRefPubMedGoogle Scholar
  19. Clezardin P, Fournier P, Boissier S, Peyruchaud O (2003) In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 10(2):173–180PubMedGoogle Scholar
  20. Cohen SB (2004) An update on bisphosphonates. Curr Rheumatol Rep 6(1):59–65PubMedGoogle Scholar
  21. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9Suppl 4:14–27PubMedGoogle Scholar
  22. Coleman RE (2002) Efficacy of Zoledronic Acid and Pamidronate in Breast Cancer Patients: A Comparative Analysis of Randomized Phase III Trials. Am J Clin Oncol (CCT) 25(6 Suppl 1):S25–S31Google Scholar
  23. Conte P, Guarneri V (2004) Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9Suppl 4:28–37PubMedGoogle Scholar
  24. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL (2003) Zoledronic Acid Exhibits Inhibitory Effects on Osteoblastic and Osteolytic Metastases of Prostate Cancer. Clin Cancer Res 9:295–306PubMedGoogle Scholar
  25. Coxon JP, Oades GM, Colston KW, Kirby RS (2004) Advances in the use of bisphosphonates in the prostate cancer setting. Prostate Cancer Prostatic Dis 7(2):99–104CrossRefPubMedGoogle Scholar
  26. Croucher P, Jagdev S, Coleman R (2003) The anti-tumor potential of zoledronic acid. The Breast (Suppl 2):30–36Google Scholar
  27. Dallas SL, Rosser JL, Mundy GR, Bonewald LF (2002) Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 14 277(24):21352–21360Google Scholar
  28. Damron TA, Sim FH (2000) Surgical treatment for metastatic disease of the pelvis and the proximal end of the femur. Instr Course Lect 49:461–470PubMedGoogle Scholar
  29. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK (2003) Mrc Pr05 Collaborators. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 95(17):1300–1311PubMedGoogle Scholar
  30. Demers LM, Costa L, Lipton A (2003) Biochemical markers and skeletal metastases. Clin Orthop (415 Suppl):S138–147PubMedGoogle Scholar
  31. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G (2003) Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 23(11):649–654CrossRefPubMedGoogle Scholar
  32. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339(6):357–363CrossRefPubMedGoogle Scholar
  33. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5(12):3914–3919PubMedGoogle Scholar
  34. Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2004) MF 4265 Study Group. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40(11):1704–1712CrossRefPubMedGoogle Scholar
  35. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A (2002) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (3):CD003188PubMedGoogle Scholar
  36. Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ (2004) Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 45(4):521–528CrossRefPubMedGoogle Scholar
  37. Elomaa I, Blomqvist C (1995) Clodronate and other biophosphonates as supportive therapy in osteolysis due to malignancy. Acta Oncol 34:629–636PubMedGoogle Scholar
  38. Enright K, Clemons M, Chow E (2004) Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. Support Care Cancer 12(1):48–52. Epub 2003 Oct 24CrossRefPubMedGoogle Scholar
  39. Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E (2003) A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 42(5–6):620–633PubMedGoogle Scholar
  40. Ferrari SL, Deutsch S, Choudhury U, Chevalley T, Bonjour JP, Dermitzakis ET, Rizzoli R, Antonarakis SE (2004) Polymorphisms in the Low-Density Lipoprotein Receptor-Related Protein 5 (LRP5) Gene Are Associated with Variation in Vertebral Bone Mass, Vertebral Bone Size, and Stature in Whites. Am J Hum Genet 74(5):866–875CrossRefPubMedGoogle Scholar
  41. Fleisch H, Russel RGG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262–1264PubMedGoogle Scholar
  42. Fohr B, Dunstan CR, Seibel MJ (2003) Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 88(11):5059–5075CrossRefPubMedGoogle Scholar
  43. Foo SS, Ramdave S, Berlangieri SU, Scott AM (2004) Detection of occult bone metastases of lung cancer with fluorine-18 fluorodeoxyglucose positron emission tomography. Australas Radiol 48(2):214–216CrossRefPubMedGoogle Scholar
  44. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clézardin P (2002) Bisphosphonates Inhibit Angiogenesis in Vitro and Testosterone-stimulated Vascular Regrowth in the Ventral Prostate in Castrated Rats. Cancer Res 62:6538–6544PubMedGoogle Scholar
  45. Frassica DA (2003) General principles of external beam radiation therapy for skeletal metastases. Clin Orthop (415 Suppl):S158–164PubMedGoogle Scholar
  46. Garcia JR, Simo M, Perez G, Soler M, Lopez S, Setoain X, Lomena F (2003) 99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer patients: different affinity between lytic and sclerotic bone metastases. Eur J Nucl Med Mol Imaging 30(12):1714. Epub 2003 Nov 19CrossRefPubMedGoogle Scholar
  47. Green JR, Clezardin P (2002) Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 25(6 Suppl l):S3–9PubMedGoogle Scholar
  48. Green JR (2004) Bisphosphonates: Preclinical Review The Oncologist 9(Suppl 4):3–13Google Scholar
  49. Guise TA, Mohammad KS (2004) Endothelins in bone cancer metastases. Cancer Treat Res 118:197–212PubMedGoogle Scholar
  50. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22(14):2942–2953CrossRefPubMedGoogle Scholar
  51. Healey JH, Brown HK (2000) Complications of bone metastases: surgical management. Cancer 88(12 Suppl):2940–2951PubMedGoogle Scholar
  52. Heidenreich A (2003) Bisphosphonates in the management of metastatic prostate cancer. Oncology 65(Suppl 1):5–11PubMedGoogle Scholar
  53. Heymann D, Ory B, Gouin F, Green JR, Redini F (2004) Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 10(7):337–343CrossRefPubMedGoogle Scholar
  54. Higano CS (2003) Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 21(5):392–398PubMedGoogle Scholar
  55. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21(21):4042–4057. Epub 2003 Sep 08.CrossRefPubMedGoogle Scholar
  56. Hiraga T, Ueda A, Tamura D, Hata K, Ikeda F, Williams PJ, Yoneda T (2003) Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4Tl/luc mouse breast cancer. Int J Cancer 106(6):973–979CrossRefPubMedGoogle Scholar
  57. Hiraga T, Williams PJ, Mundy GR, Yoneda T (2001) The Bisphosphonate Ibandronate Promotes Apoptosis in MDA-MB-231 Human Breast Cancer Cells in Bone Metastases. Cancer Res 61:4418–4424PubMedGoogle Scholar
  58. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10(13):4559–4567CrossRefPubMedGoogle Scholar
  59. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16(6):2038–2044PubMedGoogle Scholar
  60. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785–1791CrossRefPubMedGoogle Scholar
  61. Hoskin PJ (2003) Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29(4):321–327CrossRefPubMedGoogle Scholar
  62. Hou MF, Lin SB, Yuan SS, Tsai LY, Tsai SM, Hsieh JS, Huang TJ (2002) Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients. Ann Clin Lab Sci 33(1):55–61Google Scholar
  63. Katagiri T, Takahashi N (2002) Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8(3):147–159CrossRefPubMedGoogle Scholar
  64. Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91(4):718–729CrossRefPubMedGoogle Scholar
  65. Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142(12):5050–5055CrossRefPubMedGoogle Scholar
  66. Kouloulias V, Matsopoulos G, Kouvaris J, Dardoufas C, Bottomley A, Varela M, Uzunoglu N, Antypas C, Metafa A, Moulopoulos A, Sandilos P, Vlahos L (2003) Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys 57(1):143–157CrossRefPubMedGoogle Scholar
  67. Kouloulias VE, Kouvaris JR, Mystakidou K, Varela MN, Kokakis J, Pistevou-Gombaki K, Balafouta M, Gennatas C, Vlahos LJ (2004) Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer. Curr Med Res Opin 20(6):819–826PubMedGoogle Scholar
  68. Krempien R, Huber PE, Harms W, Treiber M, Wannen-macher M, Krempien B (2003) Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer 98(6):1318–1324CrossRefPubMedGoogle Scholar
  69. Kronenberg HM (2003) Developmental regulation of the growth plate. Nature 423(6937):332–336CrossRefPubMedGoogle Scholar
  70. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384–392PubMedGoogle Scholar
  71. Liepe K, Kropp J, Runge R, Kotzerke J (2003) Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 89(4):625–629CrossRefPubMedGoogle Scholar
  72. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G (2004) Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 10(18 Pt 2):6397S–6403SPubMedGoogle Scholar
  73. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090CrossRefPubMedGoogle Scholar
  74. Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98(5):962–969CrossRefPubMedGoogle Scholar
  75. Lipton A (2003) Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 8(2):469–488CrossRefPubMedGoogle Scholar
  76. Lipton A (2003) Bisphosphonates and metastatic breast cancer. Cancer 97(3 Suppl):848–853PubMedGoogle Scholar
  77. Lipton A (2004) Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2(3):205–213; discussion 213–214, 216–217, 219–220PubMedGoogle Scholar
  78. Lipton A (2004) Toward new horizons: the future of bisphosphonate therapy. Oncologist 9(Suppl 4):38–47PubMedGoogle Scholar
  79. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ (2003) Radionuclide bone imaging: an illustrative review. Radiographics 23(2):341–358PubMedGoogle Scholar
  80. Maffioli L, Florimonte L, Pagani L, Butti I, Roca I (2004) Current role of bone scan with phosphonates in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging 31(Suppl 1):S143–148. Epub 2004 Apr 16PubMedGoogle Scholar
  81. Magnetto S, Boissier S, Delmas PD, Clezardin P (1999) Additive antitumor activities of Taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast cancer cells to bone. Int J Cancer 83:263–269CrossRefPubMedGoogle Scholar
  82. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19(2):558–567PubMedGoogle Scholar
  83. Major P (2002) The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 7(6):481–491CrossRefPubMedGoogle Scholar
  84. Major PP, Coleman RE (2001) Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program Seminars in Oncology 28(2 Suppl 6):17–24Google Scholar
  85. Major PP, Cook R (2002) Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 25(6 Suppl l):S10–18PubMedGoogle Scholar
  86. Mancini I, Dumon JC, Body JJ (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22(17):3587–3592CrossRefPubMedGoogle Scholar
  87. Montague R, Hart CA, George NJ, Ramani VA, Brown MD, Clarke NW (2004) Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol 46(3):389–401CrossRefPubMedGoogle Scholar
  88. Montemurro F, Russo F, Martincich L, Cirillo S, Gatti M, Aglietta M, Regge D (2004) Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. Acta Radiol 45(1):71–74PubMedGoogle Scholar
  89. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584–593CrossRefPubMedGoogle Scholar
  90. Neudert M, Fischer C, Krempien B, Bauss F, Seibel MJ (2003) Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 107(3):468–477CrossRefPubMedGoogle Scholar
  91. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW (2003) Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170(1):246–252CrossRefPubMedGoogle Scholar
  92. Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiophar-maceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45(8):1358–1365PubMedGoogle Scholar
  93. Pavlakis N, Stockier M (2002) Bisphosphonates for breast cancer. Cochrane Database Syst Rev (1):CD003474Google Scholar
  94. Pecherstorfer M, Diel IJ (2004) Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Support Care Cancer [Epub ahead of print]Google Scholar
  95. Perry CM, Figgitt DP (2004) Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 64(11):1197–211CrossRefPubMedGoogle Scholar
  96. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE (1995) A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72:1289–1293PubMedGoogle Scholar
  97. Reszka AA, Rodan GA (2004) Nitrogen-containing biophosphonate mechanism of action. Mini Rev Med Chem 4(7):711–719PubMedGoogle Scholar
  98. Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692–2696PubMedGoogle Scholar
  99. Rogers MJ (2004) From Molds and Macrophages to Mevalonate: A Decade of Progress in understanding the Molecular Mode of Action of Bisphosphonates. Calcif Tissue Int [Epub ahead of print]Google Scholar
  100. Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9(32):2643–2658CrossRefPubMedGoogle Scholar
  101. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655–1664CrossRefPubMedGoogle Scholar
  102. Rosen L, Harland SJ, Oosterlinck W (2002) Broad Clinical Activity of Zoledronic Acid in Osteolytic to Osteoblastic Bone Lesions in Patients With a Broad Range of Solid Tumors. Am J Clin Oncol (CCT) 25(6 Suppl 1):S19–S24Google Scholar
  103. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-Term Efficacy and Safety of Zoledronic Acid Compared with Pamidronate Disodium in the Treatment of Skeletal Complications in Patients with Advanced Multiple Myeloma or Breast Carcinoma. A Randomized, Double-Blind, Multicenter, Comparative Trial. Cancer 98(8):1735–1744CrossRefPubMedGoogle Scholar
  104. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-Term Efficacy and Safety of Zoledronic Acid in the Treatment of Skeletal Metastases in Patients with Nonsmall Cell Lung Carcinoma and Other Solid Tumors. A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial. Cancer 100(12):2613–2621CrossRefPubMedGoogle Scholar
  105. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial — The zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21(16):3150–3157CrossRefPubMedGoogle Scholar
  106. Rosen LS, Gordon DH, Dugan W Jr et al. (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36–43PubMedGoogle Scholar
  107. Rosen LS (2004) New generation of bisphosphonates: broad clinical utility in breast and prostate cancer. Oncology (Huntingt) 18(5 Suppl 3):26–32PubMedGoogle Scholar
  108. Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, Broadley K (2004) A systematic review of the role of bisphosphonates in metastatic disease. Health Technology Assessment 8(4)1–192PubMedGoogle Scholar
  109. Russell RGG, Rogers MJ (1999) Bisphosphonates: From the Laboratory to the Clinic and Back Again. Bone 25(1):97–106CrossRefPubMedGoogle Scholar
  110. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468PubMedGoogle Scholar
  111. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879–882PubMedGoogle Scholar
  112. Saad F, Schulman CC (2004) Role of bisphosphonates in prostate cancer. Eur Urol 45(1):26–34CrossRefPubMedGoogle Scholar
  113. Saad F (2002) Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol 29(6 Suppl 21):19–27CrossRefPubMedGoogle Scholar
  114. Saad F (2002) Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 1(3):145–152PubMedGoogle Scholar
  115. Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G (2004) Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. Bio Drugs 18(4):269–278Google Scholar
  116. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S, Tonini G (2003) The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14(10):1468–1476CrossRefPubMedGoogle Scholar
  117. Santini D, Vincenzi B, Dicuonzo G, Awisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9(8):2893–2897PubMedGoogle Scholar
  118. Scheffler J, Derejko M, Bandurski T, Romanowicz G (2003) Application of rhenium-188 HEDP in bone metastases therapy. Nucl Med Rev Cent East Eur 6(1):55–57PubMedGoogle Scholar
  119. Schutze N, Lechner A, Groll C, Siggelkow H, Hüfner M, Köhrle J, Jakob F (1998) The human analog of murine cystein rich protein 61 [correction of 16] is a 1alpha, 25-dihydroxyvitamin D3 responsive immediate early gene in human fetal osteoblasts: regulation by cytokines, growth factors, and serum. Endocrinology 139(4):1761–1770CrossRefPubMedGoogle Scholar
  120. Seibel MJ, Koeller M, Van der Velden B, Diel I (2002) Long-term variability of bone turnover markers in patients with non-metastatic breast cancer. Clin Lab 48(11–12):579–582PubMedGoogle Scholar
  121. Seibel MJ, Koeller M, Van der Velden B, Diel I (2002) Markers of bone turnover do not predict bone metastases in breast cancer. Clin Lab 48(11–12):583–588PubMedGoogle Scholar
  122. Sloan EK, Anderson RL (2002) Genes involved in breast cancer metastasis to bone. Cell Mol Life Sci 59(9):1491–1502PubMedGoogle Scholar
  123. Smith MR, Eastham J, Gleason DM, Shasha D, Tchek-medyian S, Zinner N (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169(6):2008–2012CrossRefPubMedGoogle Scholar
  124. Smith MR (2003) Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J Urol 170(6 Pt 2):S55–57PubMedGoogle Scholar
  125. Smith MR (2004) Osteoclast-targeted Therapy for Prostate Cancer. Curr Treat Options Oncol 5(5):367–375PubMedGoogle Scholar
  126. Stewart DA, Cooper CR, Sikes RA (2004) Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reprod Biol Endocrinol 2(1):2CrossRefPubMedGoogle Scholar
  127. Swanson KC, Pritchard DJ, Sim FH (2000) Surgical treatment of metastatic disease of the femur. J Am Acad Orthop Surg 8(1):56–65PubMedGoogle Scholar
  128. Taichman R, Reilly M, Verma R, Ehrenman K, Emerson S (2001) Hepatocyte growth factor is secreted by osteoblasts and cooperatively permits the survival of haematopoietic progenitors. Br J Haematol 112(2):438–448CrossRefPubMedGoogle Scholar
  129. Terpos E, Rahemtulla A (2004) Bisphosphonate treatment for multiple myeloma. Drugs Today (Barc) 40(1):29–40CrossRefGoogle Scholar
  130. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17(3):846–854PubMedGoogle Scholar
  131. Troen BR (2003) Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 38(6):605–614CrossRefPubMedGoogle Scholar
  132. Valleala H, Hanemaaijer R, Mandelin J, Salminen A, Teronen O, Monkkonen J, Konttinen YT (2003) Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci 73(19):2413–2420CrossRefPubMedGoogle Scholar
  133. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291(3):680–686CrossRefPubMedGoogle Scholar
  134. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA (2004) Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42(2):164–175PubMedGoogle Scholar
  135. Westermann AM (2004) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 15(3):537–538CrossRefPubMedGoogle Scholar
  136. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1):200–206. Epub 2003 Mar 06CrossRefPubMedGoogle Scholar
  137. Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A (2003) Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 26(4):S92–97CrossRefPubMedGoogle Scholar
  138. Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, Ludwig H, Ziegler R, Seibel MJ (2001) Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84(3):344–351CrossRefPubMedGoogle Scholar
  139. Yano S, Zhang H, Hanibuchi M, Miki T, Goto H, Uehara H, Sone S (2003) Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clin Cancer Res 9(14):5380–5385PubMedGoogle Scholar
  140. Yoneda T, Hashimoto N, Hiraga T (2004) Bisphosphonate actions on bone and visceral metastases. Cancer Treat Res 118:213–229PubMedGoogle Scholar
  141. Yoneda T, Hashimoto N, Hiraga T (2003) Bisphosphonate actions on cancer. Calcif Tissue Int 73(4):315–318. Epub 2003 Jul 24CrossRefPubMedGoogle Scholar
  142. Zhang H, Tian M, Li S, Liu J, Tanada S, Endo K (2003) Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm 18(5):719–726CrossRefPubMedGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2006

Authors and Affiliations

  • R. Ebert
    • 1
  • F. Jakob
    • 1
  1. 1.Orthopädisches Zentrum für Muskuloskelettale ForschungOrthopädische Universitätsklinik, König-Ludwig-HausWürzburg

Personalised recommendations